Nat Med:激素鸢尾素或能有效减缓阿尔兹海默病的进展

2019-01-12 佚名 细胞

近日,一项刊登在国际杂志Nature Medicine上的研究报告中,来自皇后大学等机构的科学家们通过研究鉴别出了一种运动相关的激素,该激素或能帮助有效减缓阿尔兹海默病的进展。

近日,一项刊登在国际杂志Nature Medicine上的研究报告中,来自皇后大学等机构的科学家们通过研究鉴别出了一种运动相关的激素,该激素或能帮助有效减缓阿尔兹海默病的进展。

研究者表示,鸢尾素(irisin)是一种因运动/锻炼而产生的机体激素,其在大脑功能上扮演着关键角色,阿尔兹海默病患者机体中携带的鸢尾素水平较低;本文研究结果或能帮助研究人员深入研究开发一种药物来在大脑中再现运动诱导的鸢尾素产生的效果。

De Felice博士说道,在过去很多年里,来自全球多地的科学家通过研究发现,锻炼是一种有效的工具,其能帮助有效抑制诸如阿尔兹海默病等多种形式的痴呆症;目前很多研究人员都想通过研究寻找负责大脑中锻炼所产生保护性效应的分子。因为鸢尾素能帮助拯救破坏的突触,从而促进大脑细胞之间的交流以及记忆产生,因此其或许有望作为一种药物来帮助抵御阿尔兹海默病患者的记忆缺失。

这项研究非常重要,因为治疗痴呆症是目前科学家们面临的一项非常严峻的挑战,很不幸的是,尽管研究人员花费了30年时间来寻找药物疗法,但目前并未找到或开发出一种能有效治疗阿尔兹海默病的药物,而且绝大多数痴呆症患者可能会因为其它与年龄有关的疾病而致残,此外,让患者进行有规律的体力活动也是非常有难度的。

而增加大脑中鸢尾素产生的药物或许就是治疗阿尔兹海默病的关键;研究者De Felice说道,我们需要知道的是,阿尔兹海默病是一种非常复杂的疾病,在患者大脑发生不可逆转的改变之前,我们很难对其进行治疗,这是因为,当患者被诊断为阿尔兹海默病时,其大脑就已经发生损伤了,因此寻找新的保护性措施,比如鉴别一种锻炼相关的成分,或许就能作为一种有效的策略,在患者大脑细胞死亡及痴呆症不可逆转之前有效对患者进行治疗。

原始出处:

Mychael V. Lourenco, et al.Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer's models.Nat Med. 2019 Jan;25(1):165-175.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1883528, encodeId=85ab18835282d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 29 01:03:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926649, encodeId=398d192664979, content=<a href='/topic/show?id=071f1029e0b8' target=_blank style='color:#2F92EE;'>#鸢尾素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102970, encryptionId=071f1029e0b8, topicName=鸢尾素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Sep 27 22:03:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402776, encodeId=9bc11402e7694, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Mon Jan 14 02:03:00 CST 2019, time=2019-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609484, encodeId=5cb816094844f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jan 14 02:03:00 CST 2019, time=2019-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357941, encodeId=297535e941fb, content=锻炼防痴呆, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Jan 12 19:55:41 CST 2019, time=2019-01-12, status=1, ipAttribution=)]
    2019-03-29 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1883528, encodeId=85ab18835282d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 29 01:03:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926649, encodeId=398d192664979, content=<a href='/topic/show?id=071f1029e0b8' target=_blank style='color:#2F92EE;'>#鸢尾素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102970, encryptionId=071f1029e0b8, topicName=鸢尾素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Sep 27 22:03:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402776, encodeId=9bc11402e7694, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Mon Jan 14 02:03:00 CST 2019, time=2019-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609484, encodeId=5cb816094844f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jan 14 02:03:00 CST 2019, time=2019-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357941, encodeId=297535e941fb, content=锻炼防痴呆, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Jan 12 19:55:41 CST 2019, time=2019-01-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1883528, encodeId=85ab18835282d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 29 01:03:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926649, encodeId=398d192664979, content=<a href='/topic/show?id=071f1029e0b8' target=_blank style='color:#2F92EE;'>#鸢尾素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102970, encryptionId=071f1029e0b8, topicName=鸢尾素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Sep 27 22:03:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402776, encodeId=9bc11402e7694, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Mon Jan 14 02:03:00 CST 2019, time=2019-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609484, encodeId=5cb816094844f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jan 14 02:03:00 CST 2019, time=2019-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357941, encodeId=297535e941fb, content=锻炼防痴呆, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Jan 12 19:55:41 CST 2019, time=2019-01-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1883528, encodeId=85ab18835282d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 29 01:03:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926649, encodeId=398d192664979, content=<a href='/topic/show?id=071f1029e0b8' target=_blank style='color:#2F92EE;'>#鸢尾素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102970, encryptionId=071f1029e0b8, topicName=鸢尾素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Sep 27 22:03:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402776, encodeId=9bc11402e7694, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Mon Jan 14 02:03:00 CST 2019, time=2019-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609484, encodeId=5cb816094844f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jan 14 02:03:00 CST 2019, time=2019-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357941, encodeId=297535e941fb, content=锻炼防痴呆, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Jan 12 19:55:41 CST 2019, time=2019-01-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1883528, encodeId=85ab18835282d, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 29 01:03:00 CST 2019, time=2019-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926649, encodeId=398d192664979, content=<a href='/topic/show?id=071f1029e0b8' target=_blank style='color:#2F92EE;'>#鸢尾素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102970, encryptionId=071f1029e0b8, topicName=鸢尾素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Sep 27 22:03:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402776, encodeId=9bc11402e7694, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Mon Jan 14 02:03:00 CST 2019, time=2019-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609484, encodeId=5cb816094844f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jan 14 02:03:00 CST 2019, time=2019-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=357941, encodeId=297535e941fb, content=锻炼防痴呆, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Jan 12 19:55:41 CST 2019, time=2019-01-12, status=1, ipAttribution=)]
    2019-01-12 lovetcm

    锻炼防痴呆

    0

相关资讯

J Am Geriatr Soc:锻炼或能有效改善老年人的阿尔兹海默病症状

近期,来自康涅狄格大学的研究人员通过对此前多年的研究进行分析发现了大量的证据,即锻炼能够有效减缓阿尔兹海默病患者大脑认知功能的下降,相关研究刊登于国际杂志《Journal of the American Geriatrics Society》上。

杜怡峰:应重视阿尔茨海默病诊断的临床症状标志物

阿尔茨海默病(AD)是一种中枢神经系统变性病,起病隐袭,病程呈慢性进行性,是老年期痴呆最常见的一种类型。主要表现为渐进性记忆障碍、理解力差、定向力丧失,伴幻觉、妄想、日常生活能力下降等。2011年美国国立衰老研究院和阿尔兹海默病协会(NIA-AA)诊断标准认为AD是一个包含轻度认知损害(MCI)在内的连续疾病过程,并将生物标志物纳入到AD的诊断标准当中,这其中“临床症状标志物”具有较重要的临床意义

Mol Psychiatry:突破!科学家将阿尔兹海默病分为六种疾病亚型

近日,一项刊登在国际杂志Molecular Psychiatry上的研究报告中,来自华盛顿大学等机构的科学家们通过对阿尔兹海默病进行研究开发了一种新方法能对该病患者进行分类,相关研究或能帮助研究人员后期开发出阿尔兹海默病的新型个体化疗法。

Radiology:对于阿尔兹海默病&轻度认知障碍,哪种检查更敏感呢?

本研究旨在比较阿尔兹海默病(AD)和轻度认知障碍(MCI)在PET/MR低灌注和低代谢与健康对照(HC)受试者的差异,并将结果发表在Radiology上。

Radiology:基于MR成像的内嗅皮层视觉评分系统(ERICA评分)在诊断AD中的价值

由于内嗅皮层是阿尔兹海默病首先受累的结构,本研究旨在建立和评价对内嗅皮层的视觉评分,并将结果发表在Radiology上。

Alzheimer''s & Dementia:99.9%新药研发失败诅咒有望被打破!科学家终于揭秘APOE4突变导致阿尔茨海默病的奇特机制

本月,NIA-AA提出了新的阿尔茨海默病研究框架,它与数十年来一直使用的方法不同。后者依赖于认知变化,如记忆丧失、空间感错乱、认知障碍等,新的框架则是基于对生物标志物的检测,以实现在症状出现之前判断疾病。